Viatris: Shedding the Past
Executive Summary
Old drugs and a poorly-integrated infrastructure were all many saw in the last sizeable chunk of Degussa's Asta Medica drugs business. But Advent International and a new management team reckon they can transform what's now known as Viatris into a European in-licensing partner of choice.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?